Chimeric Peptide‐Engineered Self‐Delivery Nanomedicine for Photodynamic‐Triggered Breast Cancer Immunotherapy by Macrophage Polarization
Small · 2024
DOI: 10.1002/smll.202309994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Yi-Bin Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricu…. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunotherapy, Photochemotherapy, Macrophages. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Guangdong Special Support Program innovation team.
Abstract (Originalsprache)
A systemic treatment strategy is urgently demanded to suppress the rapid growth and easy metastasis characteristics of breast cancer. In this work, a chimeric peptide‐engineered self‐delivery nanomedicine (designated as ChiP‐CeR) for photodynamic‐triggered breast cancer immunotherapy by macrophage polarization. Among these, ChiP‐CeR is composed of the photosensitizer of chlorine e6 (Ce6) and the TLR7/8 agonist of lmiquimod (R837), which is further modified with tumor matrix targeting peptide (Fmoc‐K(Fmoc)‐PEG 8 ‐CREKA. ChiP‐CeR is preferred to actively accumulate at the tumor site via specific recognition of fibronectin, which can eradicate primary tumor growth through photodynamic therapy (PDT). Meanwhile, the destruction of primary tumors would trigger immunogenic cell death (ICD) effects to release high‐mobility group box‐1(HMGB1) and expose calreticulin (CRT). Moreover, ChiP‐CeR can also polarize M2‐type tumor‐associated macrophages (TAMs) into M1‐type TAMs, which can activate T cell antitumor immunity in combination with ICD. Overall, ChiP‐CeR possesses superior antitumor effects against primary and lung metastatic tumors, which provide an applicable nanomedicine and a feasible strategy for the systemic management of metastatic breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, P. R.China.
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou M…
- School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China.
ORCID-Profile: Shi-Ying Li, You-Zhi Tang
Förderung
- National Key Research and Development Program of China
- Guangdong Special Support Program innovation team
Zitieren
APA
Liu, Y. B., Chen, X. Y., Yu, B. X., Cen, Y., Huang, C. Y., Yan, M. Y., Liu, Q. Q., Zhang, W., Li, S. Y., & Tang, Y. Z. (2024). Chimeric Peptide‐Engineered Self‐Delivery Nanomedicine for Photodynamic‐Triggered Breast Cancer Immunotherapy by Macrophage Polarization. Small. https://doi.org/10.1002/smll.202309994
Vancouver
Liu YB, Chen XY, Yu BX, Cen Y, Huang CY, Yan MY, et al. Chimeric Peptide‐Engineered Self‐Delivery Nanomedicine for Photodynamic‐Triggered Breast Cancer Immunotherapy by Macrophage Polarization. Small. 2024. doi:10.1002/smll.202309994
BibTeX
@article{Liu2024,
author = {Liu, Yi-Bin and Chen, Xia-Yun and Yu, Bai-Xue and Cen, Yi and Huang, Chu-Yu and Yan, Meng-Yi and Liu, Qian-Qian and Zhang, Wei and Li, Shi-Ying and Tang, You-Zhi},
title = {Chimeric Peptide‐Engineered Self‐Delivery Nanomedicine for Photodynamic‐Triggered Breast Cancer Immunotherapy by Macrophage Polarization},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202309994}
}
EUVIMED